Literature DB >> 23988690

¹⁸F-fluorodeoxyglucose uptake on positron emission tomography in mucinous adenocarcinoma.

Shuji Murakami1, Haruhiro Saito, Fumi Karino, Tetsuro Kondo, Fumihiro Oshita, Hiroyuki Ito, Haruhiko Nakayama, Tomoyuki Yokose, Kouzo Yamada.   

Abstract

BACKGROUND: The prognostic value of maximum standardized uptake value (maxSUV) on (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is known for localized pulmonary adenocarcinoma, which is most commonly non-mucinous adenocarcinoma. We examined the validity of thin-section computed tomography (TS-CT) and FDG-PET findings in mucinous adenocarcinoma.
MATERIALS AND METHODS: TS-CT and FDG-PET were performed on 25 patients with mucinous lung adenocarcinoma that was subsequently resected between January 2009 and March 2013. Based on the percentage reduction of maximum tumor diameter on the mediastinal window image compared with the diameter on the lung window image on TS-CT, tumors were classified as air-type (≥50%) or solid-type (<50%). All resected specimens were pathologically diagnosed according to the International Association for the Study of Lung Cancer (IASLC) classification, and the diameter of the pathological invasive area was assessed.
RESULTS: Most mucinous adenocarcinomas were located in the lower lobe. All except two were classified as solid-type tumor on TS-CT. Multiple regression analysis revealed the correlation of maxSUV with pathological tumor size and diameter of pathological invasive area; these two parameters showed no significant correlation with each other (r=0.354, p=0.083). maxSUV was significantly lower for tumors with invasive area ≤5 mm than for tumors with invasive area >5mm (1.62 vs. 3.77, p=0.01), but no statistically significant difference was found in terms of other pathological invasive findings such as the presence of lymphatic or vascular invasion, pleural involvement, or predominant histological subtype.
CONCLUSIONS: Most mucinous adenocarcinomas had appearances of solid-type tumor on TS-CT. maxSUV on FDG-PET indicates the pathological invasive area in mucinous adenocarcinoma as well as non-mucinous adenocarcinoma.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  FDG-PET; Mucinous adenocarcinoma; TS-CT; maxSUV

Mesh:

Substances:

Year:  2013        PMID: 23988690     DOI: 10.1016/j.ejrad.2013.07.028

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

Review 1.  Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group.

Authors:  Erman Aytaç; Fatih Aslan; Bahattin Çicek; Sibel Erdamar; Bengi Gürses; Koray Güven; Okan Falay; Tayfun Karahasanoğlu; Fatih Selçukbiricik; Uğur Selek; Banu Atalar; Emre Balık; Nurdan Tözün; İzzet Rozanes; Ali Arıcan; İsmail Hamzaoğlu; Bilgi Baca; Nil Molinas Mandel; Murat Saruç; Süha Göksel; Gökhan Demir; Fulya Ağaoğlu; Cengiz Yakıcıer; Uğur Özbek; Volkan Özben; Enis Özyar; Ahmet Levent Güner; Özlem Er; Kerim Kaban; Yasemin Bölükbaşı; Dursun Buğra; The İstanbul Group
Journal:  Turk J Gastroenterol       Date:  2019-07       Impact factor: 1.852

2.  Usefulness of (18)F-FDG PET/CT to Detect Metastatic Mucinous Adenocarcinoma Within an Inguinal Hernia.

Authors:  Hyo Jung Seo; Byung Wook Min; Jae Seon Eo; Sun Il Lee; Sang Hee Kang; Sung Yup Jung; Sang Chul Oh; Jae Gol Choe
Journal:  Nucl Med Mol Imaging       Date:  2015-10-26

3.  Pulmonary invasive mucinous adenocarcinoma mimicking pulmonary actinomycosis.

Authors:  Dongyi Zhu; Qian Zhang; Zhuanghua Rui; Shengbao Xu
Journal:  BMC Pulm Med       Date:  2022-05-06       Impact factor: 3.317

4.  Primary lung invasive adenocarcinoma misdiagnosed as infectious pneumonia in 18F-FDG PET/CT:A case report.

Authors:  Yuping Han; Yongjun Luo
Journal:  Radiol Case Rep       Date:  2021-12-31

5.  A novel nomogram to predict the overall survival of patients with colloid adenocarcinoma of the lung.

Authors:  Jun Zhang; Deruo Liu
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.